Microba Life Sciences Limited (ASX:MAP)

Market Cap	34.42M -29.6%
Revenue (ttm)	14.90M -11.8%
Net Income	-19.75M
EPS	-0.04
Shares Out	717.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,806
Open	0.0460
Previous Close	0.0490
Day's Range	0.0460 - 0.0480
52-Week Range	0.0360 - 0.1050
Beta	2.09
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 15, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 7, 2026

Data Sources Report a data error